216 related articles for article (PubMed ID: 36878807)
1. Optimizing Screening for Colorectal Cancer: An Algorithm Combining Fecal Immunochemical Test, Blood-Based Cancer-Associated Proteins and Demographics to Reduce Colonoscopy Burden.
Petersen MM; Kleif J; Jørgensen LN; Hendel JW; Seidelin JB; Madsen MR; Vilandt J; Brandsborg S; Rasmussen JS; Andersen LM; Khalid A; Ferm L; Gawel SH; Martens F; Andersen B; Rasmussen M; Davis GJ; Christensen IJ; Therkildsen C
Clin Colorectal Cancer; 2023 Jun; 22(2):199-210. PubMed ID: 36878807
[TBL] [Abstract][Full Text] [Related]
2. The multitarget fecal immunochemical test versus the fecal immunochemical test for programmatic colorectal cancer screening: a cross-sectional intervention study with paired design.
Wisse PHA; de Klaver W; van Wifferen F; Meiqari L; Bierkens M; Greuter MJE; Carvalho B; van Leerdam ME; Spaander MCW; Dekker E; Coupé VMH; de Wit M; Meijer GA
BMC Cancer; 2022 Dec; 22(1):1299. PubMed ID: 36503495
[TBL] [Abstract][Full Text] [Related]
3. Fecal MicroRNA-Based Algorithm Increases Effectiveness of Fecal Immunochemical Test-Based Screening for Colorectal Cancer.
Duran-Sanchon S; Moreno L; Gómez-Matas J; Augé JM; Serra-Burriel M; Cuatrecasas M; Moreira L; Serradesanferm A; Pozo À; Grau J; Pellisé M; Gironella M; Castells A
Clin Gastroenterol Hepatol; 2021 Feb; 19(2):323-330.e1. PubMed ID: 32113893
[TBL] [Abstract][Full Text] [Related]
4. Lower Abnormal Fecal Immunochemical Test Cut-Off Values Improve Detection of Colorectal Cancer in System-Level Screens.
Berry E; Miller S; Koch M; Balasubramanian B; Argenbright K; Gupta S
Clin Gastroenterol Hepatol; 2020 Mar; 18(3):647-653. PubMed ID: 31085338
[TBL] [Abstract][Full Text] [Related]
5. Early detection of colorectal neoplasia: application of a blood-based serological protein test on subjects undergoing population-based screening.
Kleif J; Jørgensen LN; Hendel JW; Madsen MR; Vilandt J; Brandsborg S; Andersen LM; Khalid A; Ingeholm P; Ferm L; Davis GJ; Gawel SH; Martens F; Andersen B; Rasmussen M; Christensen IJ; Nielsen HJ
Br J Cancer; 2022 Jun; 126(10):1387-1393. PubMed ID: 35091694
[TBL] [Abstract][Full Text] [Related]
6. LGALS4, CEACAM6, TSPAN8, and COL1A2: Blood Markers for Colorectal Cancer-Validation in a Cohort of Subjects With Positive Fecal Immunochemical Test Result.
Rodia MT; Solmi R; Pasini F; Nardi E; Mattei G; Ugolini G; Ricciardiello L; Strippoli P; Miglio R; Lauriola M
Clin Colorectal Cancer; 2018 Jun; 17(2):e217-e228. PubMed ID: 29352642
[TBL] [Abstract][Full Text] [Related]
7. Immunochemical fecal occult blood testing is equally sensitive for proximal and distal advanced neoplasia.
de Wijkerslooth TR; Stoop EM; Bossuyt PM; Meijer GA; van Ballegooijen M; van Roon AH; Stegeman I; Kraaijenhagen RA; Fockens P; van Leerdam ME; Dekker E; Kuipers EJ
Am J Gastroenterol; 2012 Oct; 107(10):1570-8. PubMed ID: 22850431
[TBL] [Abstract][Full Text] [Related]
8. Effects of Increasing Screening Age and Fecal Hemoglobin Cutoff Concentrations in a Colorectal Cancer Screening Program.
Wieten E; Schreuders EH; Nieuwenburg SA; Hansen BE; Lansdorp-Vogelaar I; Kuipers EJ; Bruno MJ; Spaander MC
Clin Gastroenterol Hepatol; 2016 Dec; 14(12):1771-1777. PubMed ID: 27567693
[TBL] [Abstract][Full Text] [Related]
9. Personalized colorectal cancer screening: study protocol of a mixed-methods study on the effectiveness of tailored intervals based on prior f-Hb concentration in a fit-based colorectal cancer screening program (PERFECT-FIT).
Breekveldt ECH; Toes-Zoutendijk E; de Jonge L; Spaander MCW; Dekker E; van Kemenade FJ; van Vuuren AJ; Ramakers CRB; Nagtegaal ID; van Leerdam ME; Lansdorp-Vogelaar I
BMC Gastroenterol; 2023 Feb; 23(1):45. PubMed ID: 36814185
[TBL] [Abstract][Full Text] [Related]
10. Colorectal cancer detection in an asymptomatic population: fecal immunochemical test for hemoglobin vs. fecal M2-type pyruvate kinase.
Caviglia GP; Cabianca L; Fagoonee S; Gili FM
Biochem Med (Zagreb); 2016; 26(1):114-20. PubMed ID: 26981025
[TBL] [Abstract][Full Text] [Related]
11. Clinical performance study of a fecal bacterial signature test for colorectal cancer screening.
Malagón M; Alwers E; Oliver L; Ramió-Pujol S; Sánchez-Vizcaino M; Amoedo J; de Cambra S; Serra-Pagès M; Castells A; Aldeguer X; Garcia-Gil J; Brenner H
PLoS One; 2023; 18(11):e0293678. PubMed ID: 37992030
[TBL] [Abstract][Full Text] [Related]
12. Comparison of a New-generation Fecal Immunochemical Test (FIT) With Guaiac Fecal Occult Blood Test (gFOBT) in Detecting Colorectal Neoplasia Among Colonoscopy-referral Patients.
Guimarães DP; Fregnani JH; Reis RM; Taveira LN; Scapulatempo-Neto C; Matsushita M; Silva SRM; Oliveira CZ; Longatto-Filho A; Eklund C; Paloheimo L; Mauad E; Suovaniemi O; Syrjänen K
Anticancer Res; 2019 Jan; 39(1):261-269. PubMed ID: 30591467
[TBL] [Abstract][Full Text] [Related]
13. Screening for Colorectal Cancer With Fecal Immunochemical Testing With and Without Postpolypectomy Surveillance Colonoscopy: A Cost-Effectiveness Analysis.
Greuter MJE; de Klerk CM; Meijer GA; Dekker E; Coupé VMH
Ann Intern Med; 2017 Oct; 167(8):544-554. PubMed ID: 28973514
[TBL] [Abstract][Full Text] [Related]
14. Association of time to colonoscopy after a positive fecal test result and fecal hemoglobin concentration with risk of advanced colorectal neoplasia.
Kim NH; Lim JW; Kim S; Lim JY; Kim W; Park JH; Park DI; Sohn CI; Jung YS
Dig Liver Dis; 2019 Apr; 51(4):589-594. PubMed ID: 30733186
[TBL] [Abstract][Full Text] [Related]
15. Faecal immunochemical test after negative colonoscopy may reduce the risk of incident colorectal cancer in a population-based screening programme.
Peng SM; Hsu WF; Wang YW; Lin LJ; Yen AM; Chen LS; Lee YC; Wu MS; Chen TH; Chiu HM
Gut; 2021 Jul; 70(7):1318-1324. PubMed ID: 32989019
[TBL] [Abstract][Full Text] [Related]
16. Factors associated with interval colorectal cancer after negative FIT: Results of two screening rounds in the Dutch FIT-based CRC screening program.
Breekveldt ECH; Toes-Zoutendijk E; van de Schootbrugge-Vandermeer HJ; de Jonge L; Kooyker AI; Spaander MCW; van Vuuren AJ; van Kemenade FJ; Ramakers C; Dekker E; Nagtegaal ID; van Leerdam ME; Lansdorp-Vogelaar I
Int J Cancer; 2023 Apr; 152(8):1536-1546. PubMed ID: 36444504
[TBL] [Abstract][Full Text] [Related]
17. Interval Colorectal Cancer Incidence Among Subjects Undergoing Multiple Rounds of Fecal Immunochemical Testing.
van der Vlugt M; Grobbee EJ; Bossuyt PMM; Bos A; Bongers E; Spijker W; Kuipers EJ; Lansdorp-Vogelaar I; Spaander MCW; Dekker E
Gastroenterology; 2017 Aug; 153(2):439-447.e2. PubMed ID: 28483499
[TBL] [Abstract][Full Text] [Related]
18. Colorectal Cancer Screening by Fecal Immunochemical Tests (FIT): Considerations on Sampling and Markers (Hb and Hb/Hp Complex) of Fecal Occult Blood (FOB).
Syrjänen K; Eskelinen M; Meklin J; Hendolin P; Eskelinen M; Suovaniemi O
Anticancer Res; 2024 Apr; 44(4):1513-1523. PubMed ID: 38537972
[TBL] [Abstract][Full Text] [Related]
19. Equivalency of fecal immunochemical tests and colonoscopy in familial colorectal cancer screening.
Quintero E; Carrillo M; Gimeno-García AZ; Hernández-Guerra M; Nicolás-Pérez D; Alonso-Abreu I; Díez-Fuentes ML; Abraira V
Gastroenterology; 2014 Nov; 147(5):1021-30.e1; quiz e16-7. PubMed ID: 25127679
[TBL] [Abstract][Full Text] [Related]
20. A New-Generation Fecal Immunochemical Test (FIT) Is Superior to Quaiac-based Test in Detecting Colorectal Neoplasia Among Colonoscopy Referral Patients.
Vasilyev S; Smirnova E; Popov D; Semenov A; Eklund C; Hendolin P; Paloheimo L; Syrjänen K
Anticancer Res; 2015 May; 35(5):2873-80. PubMed ID: 25964570
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]